Genetic regulation of osteoclast development and function

Osteoclasts are the principal, if not exclusive, bone-resorbing cells, and their activity has a profound impact on skeletal health. So, disorders of skeletal insufficiency, such as osteoporosis, typically represent enhanced osteoclastic bone resorption relative to bone formation. Prevention of pathological bone loss therefore depends on an appreciation of the mechanisms by which osteoclasts differentiate from their precursors and degrade the skeleton. The past five years have witnessed important insights into osteoclast formation and function. Many of these discoveries have been made through genetic experiments that involved the rare hereditary disorder osteopetrosis.

[1]  M. Zaidi,et al.  Cathepsin K, Osteoclastic Resorption, and Osteoporosis Therapy , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  A. Zallone,et al.  c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation , 2003 .

[3]  G. Gronowicz,et al.  Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. , 1998, Endocrinology.

[4]  S. Mckercher,et al.  Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.

[5]  G. Krystal,et al.  Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. , 1998, Genes & development.

[6]  E. C. Weir,et al.  A Role for Cell-Surface CSF-1 in Osteoblast-mediated Osteoclastogenesis , 2002, Calcified Tissue International.

[7]  A. Ferré-D’Amaré,et al.  Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences , 1994, Nature Genetics.

[8]  C. Remé,et al.  Fra-1 replaces c-Fos-dependent functions in mice. , 2000, Genes & development.

[9]  M. Gentile,et al.  M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. , 2000, The Journal of clinical investigation.

[10]  D. Bowtell,et al.  The Cbl protooncoprotein stimulates CSF‐1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation , 1999, The EMBO journal.

[11]  Matthew J. Silva,et al.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Network Boston.

[12]  H. Okamura,et al.  Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. , 1997 .

[13]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[14]  B. Aggarwal,et al.  Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.

[15]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[16]  K. Ravichandran,et al.  Regulation of the immune response by SHIP. , 2002, Seminars in immunology.

[17]  R. Rizzoli,et al.  Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. , 1997, The Journal of clinical investigation.

[18]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[19]  K. J. Moore Insight into the microphthalmia gene. , 1995, Trends in genetics : TIG.

[20]  G. Rodan,et al.  PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. , 1998, The Journal of clinical investigation.

[21]  T. Martin,et al.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Takeya,et al.  Large Scale Gene Expression Analysis of Osteoclastogenesisin Vitro and Elucidation of NFAT2 as a Key Regulator* , 2002, The Journal of Biological Chemistry.

[23]  S. Ralston,et al.  Paget's Disease of Bone: Evidence for a Susceptibility Locus on Chromosome 18q and for Genetic Heterogeneity , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  F. Ross,et al.  Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis via an Interleukin-1and Tumor Necrosis Factor-mediated Stimulation of Macrophage Colony-stimulating Factor Production* , 1996, The Journal of Biological Chemistry.

[25]  R. Hynes,et al.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. , 2000, The Journal of clinical investigation.

[26]  R. Pacifici,et al.  Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. , 2000, The Journal of clinical investigation.

[27]  D. Veber,et al.  Human Osteoclast Cathepsin K Is Processed Intracellularly Prior to Attachment and Bone Resorption , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  B. Gelb,et al.  Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.

[29]  N. Copeland,et al.  Mild osteopetrosis in the microphthalmia-oak ridge mouse. A model for intermediate autosomal recessive osteopetrosis in humans. , 1995, The American journal of pathology.

[30]  D. G. Walker Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells , 1975, Science.

[31]  S. Marks,et al.  Bone metabolism in the osteopetrotic rat mutation microphthalmia blanc. , 1995, Bone.

[32]  Hiroshi Takayanagi,et al.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.

[33]  G. Rodan,et al.  Inhibition of Osteoclast Function by Adenovirus Expressing Antisense Protein-tyrosine Kinase 2* , 2001, The Journal of Biological Chemistry.

[34]  Yuqiong Liang,et al.  Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification , 1999, Nature Genetics.

[35]  E. Wagner,et al.  JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms , 2002, Journal of Cell Science.

[36]  Michael C. Ostrowski,et al.  The Microphthalmia Transcription Factor Regulates Expression of the Tartrate‐Resistant Acid Phosphatase Gene During Terminal Differentiation of Osteoclasts , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  D. Ory,et al.  A Glanzmann’s mutation in β3 integrin specifically impairs osteoclast function , 2001 .

[38]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[39]  E. Jimi,et al.  Activation of NF-κB Is Involved in the Survival of Osteoclasts Promoted by Interleukin-1* , 1998, The Journal of Biological Chemistry.

[40]  E. Puscheck,et al.  Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Aggarwal,et al.  Activation of NF-κB by RANK Requires Tumor Necrosis Factor Receptor-associated Factor (TRAF) 6 and NF-κB-inducing Kinase , 1999, The Journal of Biological Chemistry.

[42]  W. Dougall,et al.  A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.

[43]  R. Wallace,et al.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.

[44]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[46]  F. Ross Interleukin 7 and estrogen-induced bone loss , 2003, Trends in Endocrinology & Metabolism.

[47]  Kozo Nakamura,et al.  RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.

[48]  R. Baron,et al.  Src-catalyzed Phosphorylation of c-Cbl Leads to the Interdependent Ubiquitination of Both Proteins* , 2001, The Journal of Biological Chemistry.

[49]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[50]  P. Schlesinger,et al.  Characterization of the Osteoclast Ruffled Border Chloride Channel and Its Role in Bone Resorption* , 1997, The Journal of Biological Chemistry.

[51]  A. Yamaguchi,et al.  Osteoclasts are present in gp130-deficient mice. , 1997, Endocrinology.

[52]  B. Gelb,et al.  Determination of Bone Markers in Pycnodysostosis: Effects of Cathepsin K Deficiency on Bone Matrix Degradation , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[53]  O. Jaillon,et al.  The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. , 2000, Bone.

[54]  S. Teitelbaum,et al.  Osteoclastic bone resorption by a polarized vacuolar proton pump. , 1989, Science.

[55]  M A Horton,et al.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. , 1997, The Journal of clinical investigation.

[56]  D. Hewett‐Emmett,et al.  Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[58]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[59]  E. Stanley,et al.  CSF‐1 stimulated multiubiquitination of the CSF‐1 receptor and of Cbl follows their tyrosine phosphorylation and association with other signaling proteins , 1999, Journal of cellular biochemistry.

[60]  G. Krystal,et al.  Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation. , 1996, Blood.

[61]  Shi Wei,et al.  Interleukin-4 Reversibly Inhibits Osteoclastogenesis via Inhibition of NF-κB and Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[62]  M. Podgornik,et al.  Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.

[63]  I. Reid,et al.  A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. , 2002, Human molecular genetics.

[64]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[65]  P. Jurdic,et al.  Podosomes in osteoclast-like cells: structural analysis and cooperative roles of paxillin, proline-rich tyrosine kinase 2 (Pyk2) and integrin αVβ3 , 2001 .

[66]  D. Bowtell,et al.  Cbl Associates with Pyk2 and Src to Regulate Src Kinase Activity, αvβ3 Integrin-Mediated Signaling, Cell Adhesion, and Osteoclast Motility , 2001, The Journal of cell biology.

[67]  Kozo Nakamura,et al.  Reciprocal Role of ERK and Nf-κb Pathways in Survival and Activation of Osteoclasts , 2000, The Journal of cell biology.

[68]  S. Nishikawa,et al.  Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption , 1999, The Journal of experimental medicine.

[69]  M. Whyte,et al.  Expansile Skeletal Hyperphosphatasia Is Caused by a 15‐Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[70]  D. Lucas,et al.  Structure, function, and biology of SHIP proteins. , 2000, Genes & development.

[71]  D. G. Walker Spleen cells transmit osteopetrosis in mice , 1975, Science.

[72]  Y. Ru,et al.  A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat. , 2002, Bone.

[73]  R. Russell,et al.  Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. , 2002, Blood.

[74]  A. Zallone,et al.  Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin , 2003, The Journal of cell biology.

[75]  Michael C. Ostrowski,et al.  Genetic and Physical Interactions betweenMicrophthalmia Transcription Factor and PU.1 Are Necessary for Osteoclast Gene Expression and Differentiation* , 2001, The Journal of Biological Chemistry.

[76]  T. Suda,et al.  Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.

[77]  A. Schulz,et al.  Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. , 2000, Human molecular genetics.

[78]  J. Clohisy,et al.  TAT Fusion Proteins Containing Tyrosine 42-deleted IκBα Arrest Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.

[79]  L. Hocking,et al.  Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. , 2002, Human molecular genetics.

[80]  L. Avioli,et al.  Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. W. Wooten,et al.  Association of the Atypical Protein Kinase C-interacting Protein p62/ZIP with Nerve Growth Factor Receptor TrkA Regulates Receptor Trafficking and Erk5 Signaling* , 2003, The Journal of Biological Chemistry.

[82]  G. Passeri,et al.  Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. , 1993, Endocrinology.

[83]  K. Ozono,et al.  Novel mutations in the a3 subunit of vacuolar H(+)-adenosine triphosphatase in a Japanese patient with infantile malignant osteopetrosis. , 2002, Bone.

[84]  Shi Wei,et al.  Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. , 2002, Endocrinology.

[85]  J. P. Scherft,et al.  Fusion disability of embryonic osteoclast precursor cells and macrophages in the microphthalmic osteopetrotic mouse. , 1985, Bone.

[86]  H. Okamura,et al.  Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. , 1998, The Journal of clinical investigation.

[87]  P. Delmas,et al.  The Collagenolytic Activity of Cathepsin K Is Unique among Mammalian Proteinases* , 1998, The Journal of Biological Chemistry.

[88]  F. Ross,et al.  RANKing the importance of measles virus in Paget's disease. , 2000, The Journal of clinical investigation.

[89]  S. Teitelbaum,et al.  Successful bone-marrow transplantation for infantile malignant osteopetrosis. , 1980, The New England journal of medicine.

[90]  R. Baron,et al.  Colony-stimulating factor-1 induces cytoskeletal reorganization and c-src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts. , 1997, The Journal of clinical investigation.

[91]  J. Eisman,et al.  Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. , 2001, The Journal of endocrinology.

[92]  L. Hofbauer,et al.  Osteoprotegerin deficiency and juvenile Paget's disease. , 2002, The New England journal of medicine.

[93]  Sridhar Ramaswamy,et al.  Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability , 2002, Cell.

[94]  P. Schlesinger,et al.  Substrate Recognition by Osteoclast Precursors Induces C-src/Microtubule Association , 1997, Journal of Cell Biology.

[95]  S. Mckercher,et al.  Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1. , 1999, Blood.

[96]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[97]  Ulrich Siebenlist,et al.  Requirement for NF-κB in osteoclast and B-cell development , 1997 .

[98]  Jacques P. Brown,et al.  Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. , 2002, American journal of human genetics.

[99]  W. Dougall,et al.  The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.

[100]  T. Yoneda,et al.  Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.

[101]  L. Notarangelo,et al.  Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis , 2000, Nature Genetics.

[102]  D. Fisher,et al.  Age-resolving Osteopetrosis: A Rat Model Implicating Microphthalmia and the Related Transcription Factor TFE3 , 1998, The Journal of experimental medicine.

[103]  A. Grey,et al.  Evidence for a functional association between phosphatidylinositol 3-kinase and c-src in the spreading response of osteoclasts to colony-stimulating factor-1. , 2000, Endocrinology.

[104]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[105]  Sakae Tanaka,et al.  Severe osteopetrosis, defective interleukin‐1 signalling and lymph node organogenesis in TRAF6‐deficient mice , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[106]  T. Martin,et al.  IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro1 , 2001, The Journal of Immunology.

[107]  E. Wagner,et al.  c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. , 1994, Science.

[108]  H. Varmus,et al.  Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. , 1997, Genes & development.

[109]  M. Diaz-Meco,et al.  The atypical protein kinase Cs , 2000, EMBO reports.

[110]  J. Aubin Perspectives: Osteoclast adhesion and resorption: The role of podosomes , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[111]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[112]  Michael C. Ostrowski,et al.  TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors. , 1999, Journal of immunology.

[113]  H. Okamura,et al.  Interleukin-18 (Interferon-γ–inducing Factor) Is Produced by Osteoblasts and Acts Via Granulocyte/Macrophage Colony-stimulating Factor and Not Via Interferon-γ to Inhibit Osteoclast Formation , 1997, The Journal of experimental medicine.

[114]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[115]  D L Lacey,et al.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[116]  R. Pacifici,et al.  Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[117]  Y. Oike,et al.  Granulocyte/macrophage colony-stimulating factor and interleukin-3 correct osteopetrosis in mice with osteopetrosis mutation. , 1999, The American journal of pathology.

[118]  A. Schulz,et al.  Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man , 2001, Cell.

[119]  B. Riggs,et al.  Estrogen and the Male Skeleton , 2002 .

[120]  D. Fisher,et al.  Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[121]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[122]  Hao Wu,et al.  Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.

[123]  X. Xie,et al.  Isolation and reconstitution of a vacuolar-type proton pump of osteoclast membranes. , 1994, The Journal of biological chemistry.

[124]  Sheila J. Jones,et al.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[125]  E. Wagner,et al.  Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation , 2000, Nature Genetics.

[126]  D. Hewett‐Emmett,et al.  Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. , 1985, The New England journal of medicine.

[127]  G. Roodman,et al.  Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. , 2001, The Journal of clinical investigation.